تاريخ الإيرادات والأرباح والتدفقات النقدية من القوائم المالية الرسمية.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage.
الرسوم البيانية التفاعلية والقوائم الكاملة ← نموذج التقييم (DCF) ←
| قائمة الدخل | TTM → 2026-07-31 | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 | 2015-10-31 | 2014-10-31 | 2013-10-31 | 2012-10-31 | 2011-10-31 | 2010-10-31 | 2009-10-31 | 2008-10-31 | 2007-10-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| إجمالي الإيرادات | $4.2B | $4.1B | $3.9B | $3.6B | $3.3B | $2.9B | $2.4B | $2.7B | $2.5B | $2.1B | $2.0B | $1.8B | $1.7B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $951M | $859M |
| إجمالي الربح | $2.7B | $2.5B | $2.6B | $2.4B | $2.1B | $2.0B | $1.5B | $1.8B | $1.6B | $1.4B | $1.2B | $1.1B | $1.1B | $1.0B | $924M | $805M | $677M | $596M | $610M | $520M | $526M |
| هامش الربح الإجمالي % | 64.7% | 60.7% | 66.6% | 65.6% | 64.7% | 66.9% | 63.1% | 66.2% | 64.5% | 63.8% | 59.6% | 59.6% | 63.5% | 64.7% | 63.9% | 60.5% | 58.4% | 55.2% | 57.4% | 54.6% | 61.2% |
| الدخل التشغيلي (EBIT) | $544M | $683M | $706M | $533M | $508M | $506M | $312M | $547M | $403M | $429M | $324M | $237M | $306M | $306M | $283M | $228M | $190M | $150M | $127M | $46M | $113M |
| هامش التشغيل % | 12.8% | 16.7% | 18.1% | 14.8% | 15.3% | 17.3% | 12.8% | 20.6% | 15.9% | 20.1% | 16.5% | 13.2% | 17.8% | 19.3% | 19.6% | 17.1% | 16.4% | 13.9% | 11.9% | 4.8% | 13.1% |
| صافي الدخل | $571M | $375M | $392M | $294M | $386M | $2.9B | $238M | $467M | $140M | $373M | $274M | $204M | $270M | $296M | $248M | $175M | $113M | $101M | $65M | ($11M) | $66M |
| هامش الربح الصافي % | 13.5% | 9.2% | 10.1% | 8.2% | 11.7% | 100.8% | 9.8% | 17.6% | 5.5% | 17.4% | 13.9% | 11.3% | 15.7% | 18.6% | 17.2% | 13.2% | 9.7% | 9.3% | 6.2% | -1.2% | 7.7% |
| EBITDA | — | $1.1B | $1.1B | $886M | $879M | $824M | $590M | $826M | $690M | $616M | $520M | $425M | $443M | $447M | $398M | $308M | $255M | $252M | $209M | $140M | $181M |
| ربحية السهم (EPS) | $2.93 | $1.87 | $1.96 | $1.48 | $1.94 | $14.77 | $1.20 | $2.33 | $0.70 | $1.88 | $1.40 | $1.03 | $1.38 | $1.49 | $1.26 | $0.91 | $0.61 | $0.55 | $0.35 | $-0.06 | $0.35 |
| الأسهم القائمة (م) | — | 200M | 200M | 199M | 199M | 199M | 198M | 200M | 199M | 198M | 196M | 197M | 196M | 199M | 197M | 193M | 186M | 182M | 187M | 179M | 190M |
المصدر: التقارير العامة للشركة (SEC). تحقق من SEC EDGAR قبل الاعتماد على أي رقم.
الميزانيات والتدفقات النقدية والبيانات الفصلية والنسب المالية الكاملة في العارض التفاعلي لـ COO. /companies/us/COO
المعلومات في هذا الموقع لأغراض تعليمية وإعلامية فقط ولا تشكل نصيحة استثمارية. لا تُنشر أسعار مستهدفة أو توصيات.
About TickerBase · Data methodology & sources · Privacy · Terms